Vanguard Personalized Indexing Management LLC Has $3.04 Million Stake in Sanofi (NASDAQ:SNY)

Vanguard Personalized Indexing Management LLC lifted its position in Sanofi (NASDAQ:SNY - Free Report) by 21.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,593 shares of the company's stock after purchasing an additional 11,404 shares during the quarter. Vanguard Personalized Indexing Management LLC's holdings in Sanofi were worth $3,044,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of SNY. POM Investment Strategies LLC bought a new stake in shares of Sanofi in the 2nd quarter valued at approximately $25,000. Frazier Financial Advisors LLC bought a new stake in Sanofi in the fourth quarter valued at $28,000. Larson Financial Group LLC raised its stake in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company's stock worth $29,000 after acquiring an additional 500 shares in the last quarter. Register Financial Advisors LLC bought a new position in shares of Sanofi during the first quarter valued at $29,000. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Sanofi in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 10.04% of the company's stock.

Sanofi Trading Down 1.1 %

NASDAQ:SNY traded down $0.63 during trading hours on Friday, hitting $57.63. The stock had a trading volume of 1,942,893 shares, compared to its average volume of 2,060,200. The business's 50 day moving average is $54.34 and its 200-day moving average is $50.48. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a market cap of $145.96 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. Sanofi has a one year low of $42.63 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion during the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.95 earnings per share. Sell-side analysts anticipate that Sanofi will post 4.25 EPS for the current fiscal year.

Analyst Ratings Changes

SNY has been the topic of a number of research analyst reports. StockNews.com lowered Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, September 11th. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday. Finally, Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a report on Friday, July 26th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.